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Abstract
Background: The aim of this review was to qualitatively synthesise studies that have investigated characteristics
of the first metatarsophalangeal joint (1st MTP) in gout and to undertake a meta-analysis to estimate the average
prevalence of acute 1st MTP arthritis across studies in people with gout.
Methods: Studies published in English were included if they involved participants who had a diagnosis of gout
and presented original findings relating to the following outcome measures associated with the 1st MTP:
epidemiology; clinical features; structural and functional characteristics; and microscopic and imaging features.
Results: Forty-five studies were included in the qualitative synthesis. 1st MTP pain was a prominent feature in
people with gout. People with 1st MTP gout reported walking- and general-disability. Structural and functional
characteristics of 1st MTP gout included hallux valgus, osteoarthritis, and restricted joint motion. Successful crystal
aspiration ranged from 81 to 91 % and positive crystal identification via microscopy ranged from 83 to 93 %
in patients with a history of 1st MTP gout. Imaging features were common at the 1st MTP including the double
contour sign, tophi and erosions. Eleven studies involving 2,325 participants were included in the meta-analysis,
providing an estimate of the average prevalence of acute 1st MTP arthritis across studies of 73 % (95 % prediction
interval 40–92 %; range 48–97 %; I2 = 93 %).
Conclusions: 1st MTP acute arthritis is highly prevalent in people with gout and has a substantial impact on
patient-reported pain and disability. Gout affects the structure and function of the 1st MTP. Microscopic and
imaging studies have demonstrated crystal deposition and joint damage at the 1st MTP in people with gout.
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Background
Gout, one of the most common forms of inflammatory
arthritis in middle-aged men, is caused by monosodium
urate (MSU) crystal deposition in joints and soft tissue
[1]. Clinically, gout is characterised by painful flares of
acute monoarthritis interspersed with asymptomatic pe-
riods. If left untreated, gout can progress to a chronic
arthritis with tophus formation and joint damage [2].
Gout is well recognised by its predilection to affect the
first metatarsophalangeal joint (1st MTP). Acute episodes
of gouty arthritis at the 1st MTP are often referred to as
podagra [3]. In recent decades, lifestyle and dietary factors
associated with hyperuricaemia have become increasingly
widespread, as has the global burden of gout [4]. Gout has
a major impact on health-related quality of life [5] and its
tendency to affect the foot is reflected in the high levels of
foot-related disability and impairment [6].
Despite the well-recognised susceptibility of the 1st
MTP to acute arthritis in gout, evident by its inclusion in
several gout diagnostic and classification criteria [7–10], a
formal synthesis of the prevalence of acute 1st MTP
arthritis in this condition has yet to be undertaken.
Furthermore, the burden of 1st MTP involvement on
patient-reported outcomes in gout is unclear. Despite the
significant role of the 1st MTP during normal gait, particu-
larly the forward transfer of body weight during propul-
sion [11, 12], it is also unclear to what extent the structure
and function of the joint is compromised in people with
gout. This systematic review aimed to qualitatively synthe-
sise studies which have investigated characteristics of the
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1st MTP in gout and to undertake a meta-analysis to pro-
vide a pooled estimate for the average prevalence of acute
1st MTP arthritis in gout across studies.
Methods
Search strategy
A comprehensive electronic search was completed in
March 2015 using the following databases: Scopus (1960
to March 2015), Medline (1966 to March 2015), CINAHL
(1937 to March 2015), SportsDiscus (1985 to March
2015), the Cochrane Library, ACR abstracts (2009 to
2013) and EULAR abstracts (2002 to 2012) with the
search terms presented in Table 1. This search was supple-
mented with hand-searching of reference lists of all poten-
tially eligible full-text articles and selected review articles.
Selection criteria
All potentially eligible articles were screened by a single
author (SS) at title, abstract, and full-text stages. The
review was conducted with reference to the Preferred
Reporting Items for Systematic review and Meta-Analysis
protocols (PRISMA) statement [13]. Studies considered
for this review were published in peer-reviewed journals
and limited to randomised controlled trials, cohort stud-
ies, case-control studies and cross-sectional studies. Peer-
reviewed conference proceedings and abstracts were also
considered for inclusion. Case reports, case series with <5
cases and review articles were excluded.
The inclusion criteria included studies published in
English, adults over 18 years old and which involved par-
ticipants who had a diagnosis of gout. Included studies
presented original findings relating to the following
outcome measures: incidence or prevalence of acute
inflammatory arthritis at the 1st MTP; clinical features of
acute gouty arthritis, intercritical gout and chronic gouty
arthropathy (including tophaceous gout) at the 1st MTP;
structural and functional characteristics of the 1st MTP;
microscopy of the 1st MTP; and imaging features of the
1st MTP including MSU crystals, bone disease and
synovial disease. Studies investigating outcomes as a
measure of pharmacological, non-pharmacological and
surgical intervention efficacy were excluded. Studies
which assessed the 1st MTP amongst other joints, but
did not report outcome measures specifically relating to
the 1st MTP, were also excluded.
Data extraction
The following data was extracted from all included pa-
pers: the first author’s last name, publication year, coun-
try where the study was conducted, the study design and
aim(s), the outcome measure(s) reported and the charac-
teristics of the gout participants including: sample size,
gender, mean age (years), mean disease duration (years)
and the method of diagnosis.
Statistical analysis
A meta-analysis was conducted to obtain an estimate of
the prevalence of acute arthritis at the 1st MTP in people
with gout at any point during the course of their disease.
Due to the expected high prevalence of acute 1st MTP
arthritis, a double arcsine transformation was adopted to
address variance instability. This transformation method
is the preferred transformation option as it avoids an
undue large weight for studies [14]. The meta-analysis
was carried out using the inverse of the variance of the
transformed proportion as study weight. The pooled
transformed prevalence was transformed back for the
final presentation of the data. The 95 % prediction inter-
vals for the average estimate of prevalence was also re-
ported [15]. A random-effects model was used and the
degree of heterogeneity was evaluated using the Higgins I2
statistic which was interpreted as follows: I2 of 25 % = low
heterogeneity, I2 of 50 % =medium heterogeneity, I2 =
75 % = high heterogeneity [16]. Statistical analysis was
undertaken in MetaXL version 2.0 (EpiGear International
Pty Ltd, Brisbane, Australia).
Results
Description of studies
Figure 1 shows a flow chart of the literature search. The
initial search identified 576 papers through database
searching and 12 papers from conference abstracts. Fol-
lowing the removal of 160 duplicates, 428 papers were
screened, of which 240 papers were considered for fur-
ther examination based upon the title and abstract.
Forty-five studies met the criteria and were included in
the review (including 4 conference abstracts published
in peer-reviewed journals [17–20] and 2 English ab-
stracts from non-English papers [21, 22]). Of the 45
studies, 8 were longitudinal cohort studies, 20 cross-
sectional studies, 10 case-control studies, 5 retrospective
Table 1 Search terms
#1 Gout* OR uric OR urate OR hyperuric*OR toph*
#2 “First metatarsophalangeal” OR “first metatarsal phalangeal” OR
hallux OR “big toe” OR “first toe” OR digit OR podagra OR “1st
mtp*” OR 1mtp* OR foot OR feet
#3 Imaging OR sonograph* OR ultraso* OR “doppler” OR radiograph*
OR xray OR “magnetic resonance” OR mri OR “computed
tomograph*” OR ct OR “dect” OR “dual energy”
#4 Histol* OR microscop*
#5 Function* OR gait OR walk* OR “plantar pressure” OR motion
Final search term: #1 AND #2 AND (#3 OR #4 OR #5)
(gout* OR uric OR urate OR hyperuric*OR toph*) AND (“first metatarsophalangeal”
OR “first metatarsal phalangeal” OR hallux OR “big toe” OR “first toe” OR
digit OR podagra OR “1st mtp*” OR 1mtp* OR foot OR feet) AND ((imaging OR
sonograph* OR ultraso* OR “doppler” OR radiograph* OR xray OR “magnetic
resonance” OR mri OR “computed tomograph*” OR ct OR “dect” OR “dual
energy”) OR (histol* OR microscop*) OR (function* OR gait OR walk* OR “plantar
pressure” OR motion))
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studies, and 2 randomised clinical trials. Details of the
45 included studies are displayed in Table 2.
The 45 included studies involved 44 different groups
of gout participants (two studies used the same partici-
pants [23, 24]) totalling a pooled sample size of 5,478
participants. Thirty-eight studies involving 5,067 partici-
pants reported gender of which 4,348 (86 %) were male.
Thirty-six studies reported mean participant age which
ranged from 28 years to 69 years. Twenty-nine studies
reported disease duration which ranged from newly di-
agnosed gout to 22 years.
Five studies did not report how patients with gout
were diagnosed [17, 19, 21, 25, 26]. Fifteen studies,
totalling 1,773 participants included only patients with
gout who were diagnosed via microscopic identifica-
tion of MSU crystals in synovial fluid/tophus aspi-
rates. Fifteen studies, totalling 1,116 participants,
diagnosed gout via the 1977 ACR criteria [7] in which
participants either had MSU-proven gout or met 6 of
the 12 clinical criteria. Of these studies, nine reported
the number of crystal-proven participants (300/656
(46 %)). Two of these studies knowingly included
patients with gout who did not meet the ACR criteria
(n = 36). The remaining seven studies included in the
review diagnosed patients with gout using other
methods detailed in Table 2 [18, 20, 27–31].
The 45 studies reported on one or more of the following
outcome measures relating to 1st MTP gout: epidemiology
(n = 14, including n = 11 articles reporting on the preva-
lence of acute 1st MTP arthritis at any point during the
course of the disease which were included in the
meta-analysis), clinical characteristics (n = 8), structural
characteristics (n = 2), functional characteristics (n = 4),
microscopy (n = 7); and imaging features (n = 19).
Epidemiology
Acute 1st MTP arthritis presenting as the manifest-
ation of gout at disease onset, ranged from 43 to 76 %
[20, 32–35]. The frequency of acute 1st MTP arthritis as
the initial manifestation of gout was not significantly dif-
ferent between genders [34–36]. However, acute 1st MTP
arthritis at any point during the disease was significantly
more frequent in men (68.6 %) compared to women
(31.8 %) [34, 36]. Two studies reported 54 and 72 % of
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Fig. 1 PRISMA flowchart
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Table 2 Details of papers included in review
Author Location Study design Aim Characteristics of gout participants Outcome measures relevant to review
Bellamy [27] Canada Longitudinal
cohort
Natural progression of 1MTP acute flares N = 11
Male 100 %
Mean age 55 years
Mean disease duration 4 years
Diagnosis: “patients presenting with classical features
of acute podagra, had experienced prior attacks of
gouty arthritis and were known to be or have been
hyperuricaemic”.
Clinical characteristics of 1MTP gout
Carter [32] USA Cross-sectional The presence of synovial inflammation during
intercritical gout
N = 72
Male 90 %
Mean age 56 years
Mean disease duration 10 years
Diagnosis: ACR criteria (incl. 42 % crystal proven)
Epidemiology of 1MTP gout
Dalbeth [58] New Zealand Cross-sectional Scoring bone erosion in gout using CT imaging N = 25
Male 75 %
Median age 60 years
Median disease duration 21 years
Diagnosis: ACR criteria (incl. 44 % crystal proven)
Imaging features of the 1MTP in gout
Dalbeth [55] New Zealand Cross-sectional Relationship between radiographic joint damage
and MSU crystal deposition using DECT imaging
N = 92
Male 93 %
Mean age 58 years
Mean disease duration 22 years
Diagnosis: ACR criteria (incl. 48 % crystal proven)
Imaging features of the 1MTP in gout
Dalbeth [54] New Zealand Cross-sectional Comparison of DECT MSU deposition in people
with gout and people with asymptomatic
hyperuricaemia
N = 33
Male = 85 %
Mean age 61 years
Mean disease duration 11 years
Diagnosis: MSU crystal proven
Imaging features of the 1MTP in gout
Deesomchok [34]* Thailand Cross-sectional Clinical pattern of gout in females and males N = 194
Male 89 %
Mean age 59 (F) 52 (M) years
Mean disease duration 3 (F) 10 (M) years
Diagnosis: ACR criteria (incl. 81 % crystal proven)
Epidemiology of 1MTP gout
DeSouza [36] Brazil Cross-sectional Clinical and laboratory features of gout in men
and women
N = 58
Male 53 %
Mean age 64 (F) 61 (M) years
Mean disease duration 9 (F) 14 (M) years
Diagnosis: ACR criteria (% crystal proven not reported)
Epidemiology of 1MTP gout
Grahame [29]* UK Retrospective Characteristics of patients with gout N = 354
Male 90 %
Mean age NR
Mean disease duration NR
Diagnosis: patients with “recurrent acute episodes
of arthritis in the presence of hyperuricaemia”
Epidemiology of 1MTP gout
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Table 2 Details of papers included in review (Continued)
Hall [28]* USA Longitudinal
cohort
Epidemiology of gout and hyperuricaemia N= 86
Male 87 %
Mean age 58 years
Mean disease duration 9 years
Diagnosis: patients who met two of the following: a
typical attack of arthritis characterised by acute pain,
usually accompanied by swelling and heat, lasting
from a few day sot 2 weeks, and followed by complete
remission of symptoms; an attack of arthritis exhibiting
a striking and prompt response to therapeutic colchicine;
the presence of hyperuricaemia.
Epidemiology of 1MTP gout
Howard [67] USA Cross-sectional Reliability of ultrasound for tophi and double
contour sign
N = 50
Male 100 %
Mean age 69 years
Mean disease duration NR
Diagnosis: ACR criteria (% crystal proven not reported)
Imaging features of the 1MTP in gout
Huppertz [31]* Germany Case-control Diagnostic accuracy of DECT and ultrasound
for detecting MSU crystal deposition
N = 39Male NR
Mean age NR
Disease duration newly diagnosed
Diagnosis: Janssens score [10] of >8 or MSU crystal
proven (46 %)
Imaging features of the 1MTP in gout
Janssens [10]* Netherlands Cross-sectional Validation of a diagnostic model to predict gout N = 209
Male 89.5 %
Mean age 59 years
Mean disease duration NR
Diagnosis: MSU crystal proven
Epidemiology of 1MTP gout
Kawenoki-Minc
[21]
Poland Cross-sectional Incidence of radiographic evidence of
degenerative articular changes in patients
with gout
N= 262
Male NR
Mean age NR
Mean disease duration NR
Diagnosis: not reported
Imaging features of the 1MTP in gout
Kennedy [30] London Cross-sectional MSU crystal presence in aspirated 1MTP
joint fluid
N = 31
Male 100 %Mean age 61 years
Mean disease duration 10 years
Diagnosis: patients who had “previously had podagra”
including 52 % who were MSU crystal proven
Microscopy in 1MTP gout
Kienhorst [37] Netherlands Longitudinal
cohort
Validation of clinical diagnosis of 1MTP gout N = 123
Male 85 %
Mean age 59 years
Mean disease duration NR
Diagnosis: MSU crystal proven
Clinical characteristics of 1MTP gout
Kim [68] Korea Cross-sectional DECT presence of MSU deposition N= 101
Male 95 %
Mean age NR
Mean disease duration NR
Diagnosis: ACR criteria (% crystal proven not reported)
Imaging features of the 1MTP in gout
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Table 2 Details of papers included in review (Continued)
Kim [43] Korea Longitudinal
cohort
Comparison of clinical outcomes of arthrodesis
and tophi excision & evaluate MRI features of
tophaceous gout
N = 15
Male 67 %
Mean age 57 yearsMean disease duration NR
Diagnosis: MSU crystal proven
Clinical characteristics of 1MTP gout;
Functional characteristics of 1MTP gout;
Imaging features of the 1MTP in gout
Lally [35]* USA Retrospective Comparison of gouty arthritis in men
and women
N = 98
Male 77 %
Mean age 63 (F) 63 (M) years
Mean disease duration 5 (F) 14 (M) years
Diagnosis: MSU crystal proven
Epidemiology of 1MTP gout
Mallinson [25] Canada Retrospective Distribution of MSU crystal deposition in gout
using DECT imaging
N = 148
Male 82 %
Mean age 61 years
Mean disease duration NR
Diagnosis: not reported
Microscopy in 1MTP gout
Mijiyawa [38]* Togo Retrospective Characteristics of patients with gout N = 106
Male 99 %
Mean age 53 years
Mean disease duration 8 yearsDiagnosis: ACR criteria
(incl. 17 % crystal proven)
Epidemiology of 1MTP gout
Kang [41] Korea Longitudinal
cohort
Ultrasound characteristics of gout & efficacy
of intra-articular steroid injection for acute
1MTP flares
N = 21
Male 86 %
Mean age 64 years
Mean disease duration NR
Diagnosis: ACR criteria (% crystal proven not reported)
Clinical characteristics of 1MTP gout;
Imaging features of the 1MTP in gout
Naredo [50] Spain Case-control Diagnostic value of ultrasound for gout N = 91
Male 100 %
Mean age 56 years
Mean disease duration 7 years
Diagnosis: MSU crystal proven
Imaging features of the 1MTP in gout
Ordonez [17] Spain Cross-sectional Reliability of ultrasound in detection of
lesion at 1MTP in gout
N = 15
Male NR
Mean age NR
Mean disease duration NR
Diagnosis: not reported
Imaging features of the 1MTP in gout
Ottaviani [52] France Longitudinal
cohort
Ultrasonography showing disappearance of
MSU crystals following urate lowering therapy
N = 16
Male 100 %
Mean age 61 years
Mean disease duration 7 years
Diagnosis: MSU crystal proven
Imaging features of the 1MTP in gout
Pascual [46] Spain Cross-sectional MSU crystal presence in aspirated 1MTP
joint fluid
N = 101
Male 98 %
Mean age 56 years
Mean disease duration 5 years
Diagnosis: ACR criteria (incl. 77 % crystal proven)
Microscopy in 1MTP gout
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Table 2 Details of papers included in review (Continued)
Pascual [69] Spain Longitudinal
cohort
Disappearance of MSU crystals following
urate lowering therapy
N = 18
Male 100 %
Mean age 56 years
Mean disease duration 10 years
Diagnosis: MSU crystal proven
Microscopy in 1MTP gout
Pelaez-Ballestas
[9]*
Mexico Cross-sectional Identifying criteria for diagnosis of
chronic gout
N = 549
Male 96 %
Mean age 50 years
Mean disease duration 12 years
Diagnosis: MSU crystal proven
Epidemiology of 1MTP gout
Radak-Perovic [22] Serbia Case-control Comparison of ultrasound and x-ray for
detection of 1MTP erosions
N = 30
Male NR
Mean age NR
Mean disease duration NR
Diagnosis: ACR criteria (% crystal proven not reported)
Imaging features of the 1MTP in gout
Roddy [24] UK Case-control Concomitant gout and osteoarthritis N = 164
Male 81 %
Mean age 63 years
Mean disease duration 10 years
Diagnosis: 91 % met ACR criteria (% crystal proven
not reported)
Epidemiology of 1MTP gout; Functional
characteristics of 1MTP gout
Roddy [51] UK Cross-sectional Ultrasound characteristics of gout N = 40
Male 78 %
Mean age 65 years
Mean disease duration 13 years
Diagnosis: ACR criteria (incl. 53 % crystal proven)
Imaging features of the 1MTP in gout
Roddy [18] UK Cross-sectional Prevalence of hallux valgus, foot pain and
disability in gout
N = 1184
Male 78 %
Mean age 66 years
Mean disease duration 12 years
Diagnosis: “Patients who had consulted their GP
about gout or been prescribed allopurinol or
colchicine within the preceding 2 years”
Clinical characteristics of 1MTP gout;
Structural characteristics of 1MTP gout
Roddy [23] UK Case-Control Nodal osteoarthritis and the risk of
developing gout
N = 164
Male 81 %
Mean age 63 years
Mean disease duration 10 years
Diagnosis: 91 % met ACR criteria (% crystal proven
not reported)
Clinical characteristics of 1MTP gout;
Structural characteristics of 1MTP gout
Rome [45] New Zealand Case-control Functional and biomechanical characteristics
of gait in people with gout
N =25
Male 75 %
Mean age 61 years
Mean disease duration 22 years
Diagnosis: ACR criteria (incl. 44 % crystal proven)
Functional characteristics of 1MTP gout
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Table 2 Details of papers included in review (Continued)
Rouault [39]* USA Case-control 1MTP aspiration as a diagnostic tool for gout N = 23Male NR
Mean age NR
Mean disease duration NR
Diagnosis: MSU crystal proven
Epidemiology of 1MTP gout; Microscopy
in 1MTP gout
Sivera [47] Spain Cross-sectional Feasibility of 1MTP aspiration for gout diagnosis N = 22
Male 82 %
Mean age 61 years
Mean disease duration NR
Diagnosis: MSU crystal proven
Microscopy in 1MTP gout
Sun [53] China Cross-sectional DECT imaging features of gout N = 80
Male 94 %
Mean age 52 years
Mean disease duration 5 years
Diagnosis: ACR criteria (% crystal proven not reported)
Imaging features of the 1MTP in gout
Taylor [33]* Multinational,
multicentre
Cross-sectional Clinical, laboratory, imaging findings in gout N = 509
Male 86 %
Mean age 60 years
Median disease duration 6 years
Diagnosis: MSU crystal proven
Epidemiology of 1MTP gout; Clinical
characteristics of 1MTP gout
Thiele [56] USA Case-control Sonographic features of gout N = 16
Male 81 %
Mean age 64 years
Mean disease duration NR
Diagnosis: MSU crystal proven
Imaging features of the 1MTP in gout
Thiele [57] USA Retrospective Detection of erosions with ultrasound and
conventional radiography in chronic gout
N = 42
Male NR
Mean age NR
Mean disease duration NR
Diagnosis: MSU crystal proven
Imaging features of the 1MTP in gout
Vreju [19] Romania Longitudinal
cohort
Importance of ultrasound in gout diagnosis N = 23
Male 53 %
Mean age 53 years
Disease duration < 1 year
Diagnosis: not reported
Imaging features of the 1MTP in gout
Wang [26] Taiwan Randomised
controlled trial
Comparison of arthroscopic removal of 1MTP
MSU crystals with medical treatment alone
N = 28
Male 100 %
Mean age 28 years
Mean disease duration 2 years
Diagnosis: not reported
Clinical characteristics of 1MTP gout;
Functional characteristics of 1MTP gout
Wallace [7]* USA Cross-sectional Development of a criteria for the classification
of arthritis due to primary gout
N = 178
Male 86 %
Mean age 56 years
Mean disease duration 10 years
Diagnosis: 88 % met ACR criteria (incl. 43 %
crystal proven)
Epidemiology of 1MTP gout
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Table 2 Details of papers included in review (Continued)
Weinberger [48] USA Case-control MSU crystals in aspirated 1MTP joint fluid N = 9
Male 100 %
Mean age 54 years
Mean disease duration 2 years
Diagnosis: MSU crystal proven
Microscopy in 1MTP gout
Wright [42] Ireland Case-control Comparison of ultrasound and x-ray for
detection of erosions in gout
N = 39
Male 100 %
Mean age 52 years
Mean disease duration 12 years
Diagnosis: ACR criteria (incl. 28 % crystal proven)
Imaging features of the 1MTP in gout
Zleik [20] USA Longitudinal
cohort
Risk & predictors additional flares in newly
diagnosed gout
N = 158
Male 73 %
Mean age 59 years
Mean disease duration Newly diagnosed
Diagnosis: via the New York, Rome or ACR criteria
(% crystal proven not reported)
Epidemiology of 1MTP gout
*Papers included in meta-analysis; NR = Not Reported
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patients with gout, respectively, experienced acute arthritis
isolated to the 1st MTP [33, 37].
Eleven studies reported the prevalence of acute 1st
MTP arthritis at any point during the course of the dis-
ease and were included in the meta-analysis [7, 9, 10, 28,
29, 31, 33–35, 38, 39]. The studies provided a pooled
sample size of 2,464 participants. In total, 87 % were
male with a mean age ranging between 50 and 63 years
old. Mean or median disease duration was reported by
eight studies and ranged from newly diagnosed to
14 years [7, 9, 28, 31, 33–35, 38]. Fifty-six percent of
2,110 participants from 10 studies demonstrated aspirate
proven gout [7, 9, 10, 28, 31, 33–35, 38, 39]. The re-
ported prevalence of acute arthritis at any point dur-
ing the course of the disease ranged from 48 to 97 %.
The pooled prevalence estimate of acute 1st MTP
arthritis across studies was 73 % (95 % prediction
interval: 40–92 %). The heterogeneity was high with
an I2 of 93 % (95 % CI: 90 %–96 %). Figure 2 pre-
sents the forest plot showing the pooled prevalence
estimate of acute 1st MTP arthritis in gout across the
included studies.
Clinical characteristics
Four studies reported the characteristics of acute 1st
MTP arthritis, which included rapid onset of extremely
severe pain and tenderness with moderate swelling, ery-
thema and inflammation [27, 37, 40]. Seventy-nine per-
cent of patients reported onset within 1 day [37].
Erythema was observed in 95 % of patients with acute
1st MTP arthritis [37]. In a study following the natural
progression of acute 1st MTP arthritis for 7 days in 11
patients, improvements in erythema and juxta-articular
skin temperature were observed by day four, while 1st
MTP pain and swelling improved in most by day five
[27]. Two studies reported pain during acute 1st MTP
arthritis using 100 mm Visual Analogue Scales (VAS)
[37, 41]. Mean patient-reported pain ranged from 54.3
to 71.1 mm [37, 41].
During intercritical periods, in the absence of acute
symptoms, a significantly greater number of patients with
gout reported current 1st MTP pain compared to healthy
matched controls (16 % vs. 6 %, respectively) [23]. One
study reported 72 % of patients with long-standing gout,
with a mean of 12 years disease duration, reported 1st
MTP pain in the previous month [18]. During clinical
examination of 78 1st MTPs from 39 patients with cur-
rently asymptomatic gout, 35 % of joints demonstrated
mild tenderness, 9 % demonstrated moderate tenderness
and 6 % demonstrated marked tenderness [42].
High levels of 1st MTP pain were reported in pa-
tients with chronic tophaceous gout affecting the 1st
MTP [26, 43], with patients scoring a mean of 7.6 cm
to 7.8 cm on a 10 cm pain VAS [43].
Structural characteristics
Structure of the 1st MTP has also been assessed in
people with gout through the presence of self-reported
hallux valgus, a structural forefoot deformity involving
lateral deviation of the hallux at the 1st MTP [18, 23]. A
case-control study involving 164 patients with gout
found that self-reported hallux valgus was significantly
more common in patients with gout [23]. However, a
larger cohort study involving 1,184 gout participants re-
vealed 36 % of patients had self-reported hallux valgus,
which the authors reported was similar to the general
population and not related to gout-specific factors [18].
Functional characteristics
Moderate to high levels of general disability and walk-
ing disability were reported using 100 mm VAS in pa-
tients with current acute 1st MTP arthritis (mean
60.0 mm to 64.1 mm) [41]. Similarly, when using the
Hallux Metatarsophalangeal-Interphalangeal section of
Fig. 2 Forest plot showing pooled study prevalence of acute 1st MTP arthritis in gout
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the American Orthopaedic Foot and Ankle Society
(AOFAS) scale [44], which provides a total score out
of 100 based on pain, range of motion, joint instabil-
ity and alignment, and activity- and footwear-related
limitations, people with 1st MTP tophi scored be-
tween 65 and 61 out of 100, where 100 indicates an
absence of pain and any joint, activity or footwear
limitation [43].
A study on 164 people with gout found a significant
association between acute 1st MTP arthritis and the
presence 1st MTP osteoarthritis, defined as restricted
motion, bony swelling and/or crepitus [24]. In a further
study of patients with severe tophaceous gout the mean
(SD) total range of motion at the 1st MTP was 19°,
which reduced to 14° in joints which also demonstrated
severe cartilage loss [43].
A study assessing foot function in 25 patients with
long-standing chronic gouty arthropathy using in-shoe
plantar pressure analysis found peak plantar pressure be-
neath the first metatarsal was greater in the gout group,
although not significantly [45]. However, peak plantar
pressure and pressure-time integrals beneath the hallux
were significantly reduced in the gout group when com-
pared to the controls, which the authors proposed
reflected an attempt to offload pain at the 1st MTP [45].
Microscopy
The success of joint fluid acquisition for the purposes of
microscopic identification of MSU crystals from the 1st
MTP ranged from 81 to 91 % [30, 46, 47]. The presence
of MSU crystals in 1st MTP fluid ranged from 83 to
89 % of currently asymptomatic 1st MTPs in patients with
gout with a history of acute 1st MTP arthritis [39, 46]. In
patients with gout with no history of acute 1st MTP arth-
ritis, 52 to 67 % of aspirated 1st MTPs were positive for
crystals [30, 39, 48]. In patients experiencing current acute
1st MTP arthritis the presence of MSU crystals ranged
from 85 to 93 % [47, 49].
The occurrence of acute 1st MTP arthritis as a diag-
nostic feature has been compared with the presence of
MSU crystals in aspirated 1st MTP fluid [10, 37]. Based
on clinical characteristics of acute 1st MTP arthritis in
159 patients, general practitioners diagnosed 98 % of pa-
tients as having gout [37]. When validated against the
presence of MSU crystals, a sensitivity of 0.99 and a spe-
cificity of 0.08 was demonstrated [37]. In a study of 328
patients with monoarthritis, Janssens [10] reported that
the 1st MTP as the location of the monoarthritis was an
independent predictor of MSU crystal presence [10].
Imaging features
Urate crystal deposition
Ultrasonography allows the visualisation of MSU crystal
deposition along the surface of articular cartilage, referred
to as the ‘double contour sign’, the presence of which
ranged from 22 to 87.5 % at the 1st MTP [41, 42, 50–52].
Naredo [50] noted the double contour sign was more fre-
quent at the dorsal aspect of the 1st MTP (62 %) com-
pared to the plantar aspect (23 %).
Dual-energy computed tomography (DECT) may be
less sensitive than ultrasound due to the lower spatial
resolution [31]. In a study of 39 patients (79 % with
newly diagnosed gout) DECT detected urate crystals in
26 % of 1st MTPs, and ultrasound in 74 % of the same
joints [31]. The presence of MSU deposition using
DECT increased from 26 % of joints in newly diagnosed
gout [25], to 36 % after 5 years disease duration [53],
and 54 % in patients with 11 years mean duration [54].
In patients with tophaceous gout and a mean disease
duration of 22 years, MSU crystals were present in 38 %
of 184 1st MTPs [55].
In a DECT study assessing feet with current flares,
the authors reported crystal deposition in 41 % of 1st
MTPs in patients with 1st MTP flares, compared to
27 % of 1st MTPs in patients with current ankle flares
[53]. The presence of DECT MSU crystal deposition
was found to be a risk factor for acute 1st MTP arth-
ritis (OR = 3.38;) [53].
Tophi
In sonographic studies, the presence of tophi in 1st
MTPs of people with gout ranged from 50 to 100 %
[41, 42, 50, 52, 56, 57]. Thiele and Schlesinger [56]
noted tophi were more often seen medial and dorsal to
the joint with a distinct pattern in which unformed micro-
particles were seen in the dorsal proximal recess and cen-
tral area while formed tophi were more frequent in the
medial compartment and impinging on the dorsal prox-
imal phalanx [56]. Using MRI, a study of 15 patients with
1st MTP tophaceous gout, reported that the medial
sesamoid was the most common location for tophaceous
infiltration (seen in 47 % of patients), followed by the
first metatarsal shaft (40 %) and lateral sesamoid (33 %)
[43]. In the majority of patients (57 %) tophi were
observed both extra-articularly and intra-articularly within
the 1st MTP.
Bone disease
In patients with long-standing tophaceous gout, ero-
sions on conventional radiography were noted in
79 % of 1st MTPs [55]. Other radiographic features
of bone damage have been observed frequently in the
1st MTP joints in people with gout including spur
formation (40 % of joints), joint space narrowing
(39 %), osteophytes (44 %), sclerosis (73 %) and peri-
osteal new bone formation (13 %) [55]. A study of
262 patients with gout reported radiographic proven
osteoarthritis (defined as destruction of the articular
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surfaces) in 44 % of 1st MTPs and found a significant
correlation between osteoarthritis and acute arthritis
at this joint [21].
Sonographic evidence of bone erosion in 1st
MTPs ranged from 40 to 67 % in patients with gout
[22, 41, 42, 56, 57]. Wright [42] reported 92 % of de-
tected erosions were present on the medial aspect of the
metatarsal head, with 7 % on the dorsal metatarsal head,
and the remaining 2 % on the medial aspect of the proximal
phalangeal base. Erosions at the 1st MTP can be multifocal
or unifocal and generally measure at least 2 mm in diam-
eter [41, 42]. Thiele and Schlesinger [56] noted all erosions
at the 1st MTP were adjacent to tophaceous material.
Using MRI, Kim [43] reported erosions and intraosseous
involvement present in the first metatarsal shaft of 40 % of
patients with symptomatic 1st MTP tophaceous gout.
Using conventional CT, Dalbeth [58] reported 78 % of 1st
MTPs had erosions present at the first metatarsal head,
and 34 % had erosions at the proximal phalanx. The pro-
portions of eroded bone were also greater at the metatar-
sal head compared to the proximal phalanx and were
higher in those with clinically-evident tophi.
Synovial disease
Synovial disease, in the form of joint effusion, synovial
hypertrophy, and synovitis has been assessed using both
gray-scale and power Doppler ultrasound [41, 42, 51, 56].
Joint effusion, which has been observed in 29 to 74 % of
1st MTPs in people with gout [41, 42, 51, 56], is less spe-
cific for gout and has been seen at a similar rate in other
rheumatic conditions (64 to 73 %) [42, 56]. Similarly, syn-
ovial hypertrophy is seen at a similar rate in gouty 1st
MTPs (53 to 87 %) [41, 42, 51], and other rheumatic con-
ditions (64 %) [42]. Synovitis, which can be assessed using
power Doppler ultrasound has been shown to be more
sensitive than clinical assessment (18 % vs. 5 %, respect-
ively) [51]. Synovitis has been reported to occur at the 1st
MTP with a mild Doppler signal in 15 %, moderate signal
in 18 % and marked signal in 10 % [42]. Synovitis occurs
at a significantly greater frequency in 1st MTPs in those
joints with acute arthritis, with Kang [41] reporting 95 %
of 1st MTPs with acute arthritis demonstrated mild to
moderate power Doppler signals. However, synovitis is
not specific to gout and is seen in 18 to 50 % of other in-
flammatory joint diseases [42, 56].
Discussion
The historical observation of gout as a condition specific-
ally affecting the 1st MTP is reflected in modern epi-
demiological literature, and is evident by the pooled 73 %
prevalence estimate of 1st MTP acute arthritis reported in
the meta-analysis of 11 studies. The clinical diversity be-
tween these studies, which is generally considered inevit-
able in meta-analyses [59], may explain the wide range of
estimated prevalence values and account for the high
heterogeneity observed. The included studies represented
patients with gout from a wide range of countries, result-
ing in different participant demographics, genetic factors
and lifestyle factors. Additionally, disease duration of gout
participants varied considerably and is likely to impact the
calculated prevalence estimate, as longer disease duration
would increase the likelihood of experiencing an episode
of acute 1st MTP arthritis. Furthermore, only 42 % of par-
ticipants included in the meta-analysis were diagnosed
with gout using the gold standard MSU crystal identifica-
tion [7, 9, 10, 28, 31, 34, 35, 38, 39]. The differences in
study designs adopted by the included studies (e.g. cohort,
cross-sectional, case-control, retrospective and rando-
mised controlled trial) may also have contributed to the
increased heterogeneity. Nevertheless, this prevalence esti-
mate provides useful quantitative data which corroborates
the traditional notion that gout is a condition with
frequent manifestations at the 1st MTP.
Pain experienced during acute 1st MTP arthritis is con-
siderable [27, 37, 41], and remains present following the
resolution of acute symptoms [18, 42]. Outcome measure-
ment methods used for measuring 1st MTP pain varied
from 5-point Likert scales [27], visual analogue scales
[37, 41], simply recording whether 1st MTP pain was
present or absent [23], to measuring tenderness with
palpation [42]. However, it appears that 1st MTP pain
is a chronic foot problem in people with gout, which
is further reflected by the sub-clinical joint inflamma-
tion observed during intercritical periods [42, 51]. In
patients with 1st MTP tophaceous gout, high levels of
pain are coupled with reduced joint function [26, 43].
Although it is unclear whether these clinical symp-
toms are a consequence of pain-avoidance, joint dam-
age, synovial inflammation, mechanical obstruction by
tophi, or a combination of these factors, the clinical
implications of symptomatic 1st MTP gout on the
ability to undertake everyday weight-bearing activities,
such as walking, are recognised as important features
of the disease [41]. People with gout walk significantly
slower and demonstrate gait patterns consistent with
1st MTP pain-avoidance strategies [45]. Abnormal 1st
MTP loading at toe-off in patients with gout may be fur-
ther exacerbated by biomechanical strain as a result of
MSU deposition within the 1st MTP flexor and extensor
tendons [53, 60].
As the initiation of acute gouty arthritis is not possible
in the absence of MSU crystals, the susceptibility of the
1st MTP to gout over other joints must be related to
certain factors which predispose to the precipitation and
deposition of crystals at this site. It has been hypothe-
sised that the predilection for MSU deposition and pa-
tient symptoms in the foot and ankle may be attributed
to the biomechanical loading or physical stress during
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the normal gait cycle [55, 56, 58, 60]. This is further
emphasised in the distinct pattern of crystal deposition
at the 1st MTP observed in imaging studies where MSU
deposits have been reported to occur more often on the
medial and dorsal aspects of the joint compared to the
plantar aspect [50, 56, 61]. It has been proposed that this
distinct pattern of crystal deposition at the 1st MTP may
result from the shifting of tophaceous deposits with
dorsiflexion during walking and their eventual clustering
at pressure points within the joint [56].
Osteoarthritis observed at the 1st MTP has also
been implicated in the co-occurrence of gout at this
joint [21, 24]. However, the distinction between joint
damage caused by chronic gouty arthritis and osteo-
arthritic joint damage is unclear, particularly due to
the high prevalence of 1st MTP osteoarthritis in the
general population [62].
This review has a number of limitations. Firstly, the lit-
erature search and screening was conducted by a single
reviewer. Secondly, the methodology adopted may have
created a selection bias through the exclusion of non-
English language studies which may have resulted in an
incompletely and potentially biased set of evidence. In
regard to the methodologies used in included studies,
most were cross-sectional descriptive studies which pro-
vide lower-level evidence and limit investigation in to the
cause-effect relationship between 1st MTP characteristics
and gout. Many of the studies also involved small sample
sizes. Furthermore, gout disease characteristics of partici-
pants in the included studies varied and the majority of
participants were diagnosed based on clinical criteria.
Although this reflects diagnostic methods employed in
clinical practice, there are several limitations to current
classification criteria [40] and the demonstration of MSU
crystals in synovial/tophus aspirates remains the only
method to permit a definitive diagnosis of gout [63].
Lastly, there is an absence of a recommended outcome
measure to assess patient-reported outcomes relating spe-
cifically to the 1st MTP in gout research which makes
comparisons between studies challenging.
This review highlights the need for future research
which adopts standardised assessment approaches when
investigating patient-reported outcomes specifically re-
lating to the 1st MTP in gout. Advanced imaging may
be implemented to determine the structural characteris-
tics of the joint in relation to clinical features, particu-
larly how 1st MTP involvement affects patient-reported
outcomes and the ability to carry out daily activities, in-
cluding walking. This may direct further research which
investigates the biomechanical role of the 1st MTP in
the frequent occurrence of gout at this joint. By recog-
nising the local factors that contribute to the 1st MTPs
susceptibility to crystal deposition and inflammation, fur-
ther studies may assess non-pharmacological interventions
that are specifically aimed at the 1st MTP including foot-
wear, foot orthoses and foot-related health education which
have previously been shown to be effective with general-
foot pain and disability in people with gout [64–66].
Conclusion
This review aimed to evaluate and summarise the find-
ings from existing literature which assessed the 1st
MTP in people with gout. This review confirms the
long-standing notion that acute 1st MTP arthritis is
highly prevalent in people with gout and has a substan-
tial impact on patient-reported outcomes related to
pain and disability. Current research also suggests that
the structure and function of the 1st MTP is impaired
in people with gout. This review highlights the import-
ance of clinical, laboratory and imaging findings related
to the 1st MTP in the diagnosis of gout in clinical prac-
tice and underlines the need for interventions that
specifically target improvements in structure, function
and patient-reported outcomes related to the 1st MTP
in people with gout.
Abbreviation
1st MTP: First metatarsophalangeal joint.
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